A011-12 SOTERIA SOTERIA - An Open-Label Long-Term Follow-Up Study to Evaluate the Effects of Sotatercept when Added to Background Pulmonary Arterial Hypertension (PAH) Therapy for the Treatment of PAH

NCT04796337

SOTERIA - An Open-Label Long-Term Follow-Up Study to Evaluate the Effects of Sotatercept when Added to Background Pulmonary Arterial Hypertension (PAH) Therapy for the Treatment of PAH

Associated Conditions

Pulmonary Hypertension

Principal Investigator

Sponsor

Accerleron Pharma

We are asking you to take part in this study because you are currently in a study with sotatercept and we want to find out if continuing to take sotatercept is safe and effective over a long period of time.

This study is currently enrolling.